News
-
-
-
COMMUNIQUÉ DE PRESSE
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
Evotec receives $10 M milestone from Bristol Myers Squibb for Phase 1 clinical study initiation of BMS-986506 in clear cell renal cell carcinoma. Collaboration focuses on protein degradation for cancer treatment -
-
-
COMMUNIQUÉ DE PRESSE
Evotec Announces ‘Horizon’ – Next Inflection in Its Strategic Transformation to Accelerate Growth and Promote Agility
Evotec SE announces 'Horizon', the next phase in its strategic transformation to accelerate growth and promote agility through a new operating model across operations, science, and commercial execution -
-
-
COMMUNIQUÉ DE PRESSE
Just – Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
Just - Evotec Biologics, a subsidiary of Evotec SE, receives grant from Gates Foundation to optimize monoclonal antibody development using AI-driven molecular design, enhancing affordability and global access -
